论文部分内容阅读
KarallieddeJ等在ADA2005年会上报告(81OR),381例T2DM(男67%),平均年龄60±9岁,糖尿病病程9.5±6.3年。既往应用磺脲或磺脲加二甲双胍。应用罗格列酮(RSG)出现体液潴留260例(男63%)。体液潴留的定义是:红细胞压积减少≥0.5%。该260例随意分5组治疗7天:继续RSG(RSG C组);RSG+速?
KarallieddeJ and other ADA2005 annual report (81OR), 381 cases of T2DM (male 67%), mean age 60 ± 9 years, duration of diabetes 9.5 ± 6.3 years. Previous use of sulfonylureas or sulfonylurea plus metformin. Body fluid retention was observed in 260 patients (63%) with rosiglitazone (RSG). Body fluid retention is defined as: hematocrit reduction ≥ 0.5%. The 260 cases were randomly divided into 5 groups treated for 7 days: continue RSG (RSG C group); RSG +